Achillion Pharmaceuticals, Inc. announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr. Gibney will assume responsibility for corporate strategy, business development, investor relations and corporate communications as Achillion continues the advancement of its proprietary factor D small molecule portfolio. Achillion also announced that Brian R. DiDonato has recently joined the Company as Vice President of Investor Relations and Corporate Communications, reporting to Mr. Gibney.